Bupropion: Difference between revisions

From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
m (Text replacement - "| pmid =" to "| pmid =")
m (Text replacement - " | doi" to " | doi")
 
(44 intermediate revisions by the same user not shown)
Line 1: Line 1:
'''Bupropion''' is an atypical [[antidepressant]] medication sold under the brand names include '''Wellbutrin''', '''Aplenzin''', and '''Zyban''', and formerly Budeprion.<ref name="medline">{{Cite web|url=https://medlineplus.gov/druginfo/meds/a695033.html|title=Bupropion: MedlinePlus Drug Information|website=medlineplus.gov|language=en|access-date=2019-01-08}}</ref><ref name="PMC2729622" /><ref name="patch" /> In addition to treating [[depression]] and severe pain, it is also used to treat [[seasonal affective disorder]] (SAD), and to reduce cravings in smoking cessation and drug addiction.<ref name="medline" /><ref name="drugscom" />
'''Bupropion''' is an atypical [[antidepressant]] medication sold under the brand names include '''Wellbutrin''', '''Aplenzin''', and '''Zyban''', and formerly Budeprion.<ref name="medline">{{Cite web | url = https://medlineplus.gov/druginfo/meds/a695033.html | title = Bupropion: MedlinePlus Drug Information | website = medlineplus.gov|language=en | access-date = 2019-01-08}}</ref><ref name="PMC2729622" /><ref name="patch" /> In addition to treating [[depression]] and severe pain, it is also used to treat [[seasonal affective disorder]] (SAD), and to reduce cravings in smoking cessation and drug addiction.<ref name="medline" /><ref name="drugscom" />


==Types==
==Types==
Line 7: Line 7:


==Theory ==
==Theory ==
Buproprion, like all antidepressants, does not address the underlying mechanisms of ME/CFS, so should not be regarded as a cure. It should be used only to reduce particular symptoms or treat a co-existing disorder (e.g. depression), and it is not a primary treatment for ME/CFS.<ref name="canadianconsensus-CCC">{{Citation | last1   = Carruthers   | first1 = Bruce M.   | authorlink1 = Bruce Carruthers | last2 = Jain   | first2 = Anil Kumar | authorlink2 = Anil Kumar Jain | last3 = De Meirleir   | first3 = Kenny L.   | authorlink3 = Kenny De Meirleir | last4   = Peterson     | first4 = Daniel L. | authorlink4 = Daniel Peterson | last5   = Klimas       | first5 = Nancy G.   | authorlink5 = Nancy Klimas | last6   = Lerner       | first6 = A. Martin | authorlink6 = Martin Lerner | last7   = Bested       | first7 = Alison C. | authorlink7 = Alison Bested | last8 = Flor-Henry   | first8 = Pierre     | authorlink8 = Pierre Flor-Henry | last9   = Joshi | first9 = Pradip     | authorlink9 = Pradip Joshi | last10 = Powles | first10 = A C Peter | authorlink10 = A C Peter Powles | last11 = Sherkey| first11 = Jeffrey A.| authorlink11 = Jeffrey Sherkey | last12 = van de Sande | first12 = Marjorie I. | authorlink12 = Marjorie van de Sande | title = Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Clinical Working Case Definition, Diagnostic and Treatment Protocols| journal = Journal of Chronic Fatigue Syndrome | volume = 11 | issue = 2 | pages = 7-115 | date = 2003| pmid = | doi     = 10.1300/J092v11n01_02| url     = http://www.investinme.org/Documents/PDFdocuments/CanadianDefinitionME-CFS.pdf}}</ref>
Buproprion, like all antidepressants, does not address the underlying mechanisms of ME/CFS, so should not be regarded as a cure. It should be used only to reduce particular symptoms or treat a co-existing disorder (e.g. depression), and it is not a primary treatment for ME/CFS.<ref name="canadianconsensus-CCC">{{Citation | last1 = Carruthers | first1 = Bruce M. | author-link1 = Bruce Carruthers | last2 = Jain | first2 = Anil Kumar | author-link2 = Anil Kumar Jain | last3 = De Meirleir | first3 = Kenny L. | author-link3 = Kenny De Meirleir | last4 = Peterson | first4 = Daniel L. | author-link4 = Daniel Peterson | last5 = Klimas | first5 = Nancy G. | author-link5 = Nancy Klimas | last6 = Lerner | first6 = A. Martin | author-link6 = Martin Lerner | last7 = Bested | first7 = Alison C. | author-link8 = Alison Bested | last8 = Flor-Henry | first8 = Pierre | author-link8 = Pierre Flor-Henry | last9 = Joshi | first9 = Pradip | author-link9 = Pradip Joshi | last10 = Powles | first10 = AC Peter | author-link10 = A C Peter Powles | last11 = Sherkey | first11 = Jeffrey A. | author-link11 = Jeffrey Sherkey | last12 = van de Sande | first12 = Marjorie I. | author-link12 = Marjorie van de Sande | title = Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Clinical Working Case Definition, Diagnostic and Treatment Protocols| journal = Journal of Chronic Fatigue Syndrome | volume = 11 | issue = 2 | pages = 7-115 | date = 2003 | pmid = | doi = 10.1300/J092v11n01_02| url = http://www.investinme.org/Documents/PDFdocuments/CanadianDefinitionME-CFS.pdf}}</ref>


ME/CFS patients may tolerate brand name bupropion better than generic versions due to sensitivities.{{Citation needed}}
ME/CFS patients may tolerate brand name bupropion better than generic versions due to sensitivities.{{Citation needed}}

Latest revision as of 00:18, April 2, 2023

Bupropion is an atypical antidepressant medication sold under the brand names include Wellbutrin, Aplenzin, and Zyban, and formerly Budeprion.[1][2][3] In addition to treating depression and severe pain, it is also used to treat seasonal affective disorder (SAD), and to reduce cravings in smoking cessation and drug addiction.[1][4]

Types[edit | edit source]

Bupropion is available in different forms, and may be combined with other drugs for particular uses, including

  • Bupropion for smoking cessation, brand name Zyban
  • Bupropion for major depression, brand name Wellbutrin[4]

Theory[edit | edit source]

Buproprion, like all antidepressants, does not address the underlying mechanisms of ME/CFS, so should not be regarded as a cure. It should be used only to reduce particular symptoms or treat a co-existing disorder (e.g. depression), and it is not a primary treatment for ME/CFS.[5]

ME/CFS patients may tolerate brand name bupropion better than generic versions due to sensitivities.[citation needed]

Evidence[edit | edit source]

Clinicians[edit | edit source]

Risks and safety[edit | edit source]

Costs and availability[edit | edit source]

Learn more[edit | edit source]

See also[edit | edit source]

References[edit | edit source]

  1. 1.0 1.1 "Bupropion: MedlinePlus Drug Information". medlineplus.gov. Retrieved January 8, 2019.
  2. Cite error: Invalid <ref> tag; no text was provided for refs named PMC2729622
  3. Cite error: Invalid <ref> tag; no text was provided for refs named patch
  4. 4.0 4.1 https://www.drugs.com/bupropion
  5. Carruthers, Bruce M.; Jain, Anil Kumar; De Meirleir, Kenny L.; Peterson, Daniel L.; Klimas, Nancy G.; Lerner, A. Martin; Bested, Alison C.; Flor-Henry, Pierre; Joshi, Pradip; Powles, AC Peter; Sherkey, Jeffrey A.; van de Sande, Marjorie I. (2003), "Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Clinical Working Case Definition, Diagnostic and Treatment Protocols" (PDF), Journal of Chronic Fatigue Syndrome, 11 (2): 7–115, doi:10.1300/J092v11n01_02